PD-L1 expression is considered a biomarker for ICI response in some tumors, although its intrinsic limitations should be reflected upon; even if PD-L1 is expressed, the lack of adequate immune infiltration into the tumor could significantly limit the efficacy of ICI treatment. This evidence concerns the gene CD274 and neoplasm.